- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1865-5076
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Neoadjuvant therapy in urothelial cancer ; volume:12 ; number:4 ; day:23 ; month:10 ; year:2019 ; pages:329-333 ; date:12.2019
Magazine of European Medical Oncology ; 12, Heft 4 (23.10.2019), 329-333, 12.2019
- Creator
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12254-019-00533-8
- URN
-
urn:nbn:de:101:1-2020040403151642365559
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:53 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Brönimann, Stephan
- D'Andrea, David
- Shariat, Shahrokh F.
- Gust, Kilian M.
- SpringerLink (Online service)
Other Objects (12)
Nonmuscle invasive urothelial cancer— Bacillus Calmette–Guérin instillation or checkpoint inhibitor immunotherapy?
PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients : Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer
ASO Author Reflections: Is Vascular Cell Adhesion Molecule-1 (VCAM-1) a Promising Biomarker in Urothelial Carcinoma of the Bladder?
Prostatakrebs : Vorbeugung, Diagnose; Therapie
Association of patients’ sex with treatment outcomes after intravesical bacillus Calmette–Guérin immunotherapy for T1G3/HG bladder cancer
Medical practice and placebo response: an inseparable bond?
Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer
Comparison between urothelial and non-urothelial urethral cancer
Focal therapy in intermediate- and high-risk prostate cancer
Functional outcomes after local salvage therapies for radiation-recurrent prostate cancer patients: a systematic review
Prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma: a systematic literature review and meta-analysis
Pre-therapy serum albumin-to-globulin ratio in patients treated with neoadjuvant chemotherapy and radical nephroureterectomy for upper tract urothelial carcinoma
Nonmuscle invasive urothelial cancer— Bacillus Calmette–Guérin instillation or checkpoint inhibitor immunotherapy?
PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients : Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer
ASO Author Reflections: Is Vascular Cell Adhesion Molecule-1 (VCAM-1) a Promising Biomarker in Urothelial Carcinoma of the Bladder?
Prostatakrebs : Vorbeugung, Diagnose; Therapie
Association of patients’ sex with treatment outcomes after intravesical bacillus Calmette–Guérin immunotherapy for T1G3/HG bladder cancer
Medical practice and placebo response: an inseparable bond?
Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer
Comparison between urothelial and non-urothelial urethral cancer
Focal therapy in intermediate- and high-risk prostate cancer
Functional outcomes after local salvage therapies for radiation-recurrent prostate cancer patients: a systematic review
Prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma: a systematic literature review and meta-analysis
Pre-therapy serum albumin-to-globulin ratio in patients treated with neoadjuvant chemotherapy and radical nephroureterectomy for upper tract urothelial carcinoma
Nonmuscle invasive urothelial cancer— Bacillus Calmette–Guérin instillation or checkpoint inhibitor immunotherapy?
PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients : Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer
ASO Author Reflections: Is Vascular Cell Adhesion Molecule-1 (VCAM-1) a Promising Biomarker in Urothelial Carcinoma of the Bladder?
Prostatakrebs : Vorbeugung, Diagnose; Therapie
Association of patients’ sex with treatment outcomes after intravesical bacillus Calmette–Guérin immunotherapy for T1G3/HG bladder cancer
Medical practice and placebo response: an inseparable bond?
Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer
Comparison between urothelial and non-urothelial urethral cancer
Focal therapy in intermediate- and high-risk prostate cancer
Functional outcomes after local salvage therapies for radiation-recurrent prostate cancer patients: a systematic review
Prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma: a systematic literature review and meta-analysis